Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:NAMSNASDAQ:VALNNASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$29.90+0.1%$23.62$16.50▼$30.38$2.60BN/A56,778 shs21,364 shsNAMSNewAmsterdam Pharma$21.84+8.3%$17.90$14.06▼$27.29$2.45B-0.03670,431 shs1.53 million shsVALNValneva$6.17+1.4%$6.45$3.62▼$8.99$515.62M1.8142,494 shs2,648 shsVCELVericel$45.70+4.3%$41.30$37.39▼$63.00$2.30B1.33417,690 shs352,512 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+5.29%+18.48%+22.91%+57.26%+2,987,999,900.00%NAMSNewAmsterdam Pharma+0.10%+6.50%+9.74%-11.89%+4.46%VALNValneva-1.12%-5.15%-6.03%-13.88%-27.48%VCELVericel+1.20%+8.30%+5.01%-8.35%-1.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/ANAMSNewAmsterdam Pharma2.6809 of 5 stars3.51.00.00.02.55.00.0VALNValneva2.6441 of 5 stars3.55.00.00.02.60.80.0VCELVericel3.2871 of 5 stars3.53.00.00.03.10.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/ANAMSNewAmsterdam Pharma 3.00Buy$43.0096.89% UpsideVALNValneva 3.00Buy$15.50151.42% UpsideVCELVericel 3.00Buy$61.1433.79% UpsideCurrent Analyst Ratings BreakdownLatest VALN, VCEL, NAMS, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025NAMSNewAmsterdam PharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$44.006/4/2025NAMSNewAmsterdam PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.005/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $40.005/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/15/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/11/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$61.00 ➝ $51.004/9/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/31/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/27/2025AAPGAscentage Pharma Group InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.66N/AN/AN/A∞NAMSNewAmsterdam Pharma$47.14M52.02N/AN/A$3.50 per share6.24VALNValneva$186.06M2.77N/AN/A$2.00 per share3.08VCELVericel$238.54M9.64$0.01 per share3,081.95$4.73 per share9.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/ANAMSNewAmsterdam Pharma-$176.94M-$1.88N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)VALNValneva-$109.78M-$1.19N/AN/AN/A-4.35%-3.93%-1.42%8/12/2025 (Estimated)VCELVericel-$3.18M$0.03761.79103.86N/A1.56%1.48%0.96%7/30/2025 (Estimated)Latest VALN, VCEL, NAMS, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million5/7/2025Q1 2025VALNValneva-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million3/20/2025Q4 2024VALNValneva-$0.22-$0.54-$0.32-$0.54$55.64 million$56.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/ANAMSNewAmsterdam PharmaN/A10.6110.61VALNValneva0.702.782.25VCELVericelN/A4.614.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ANAMSNewAmsterdam Pharma89.89%VALNValneva11.39%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ANAMSNewAmsterdam Pharma20.84%VALNValneva14.91%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.11 millionN/AN/ANAMSNewAmsterdam Pharma4112.27 million74.37 millionOptionableVALNValneva70083.64 million69.15 millionNot OptionableVCELVericel30050.34 million46.79 millionOptionableVALN, VCEL, NAMS, and AAPG HeadlinesRecent News About These CompaniesVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 10 at 8:30 AM | globenewswire.comGAMMA Investing LLC Acquires 127,028 Shares of Vericel Co. (NASDAQ:VCEL)June 10 at 3:32 AM | marketbeat.comVericel Co. (NASDAQ:VCEL) Receives $61.14 Consensus PT from AnalystsJune 10 at 2:15 AM | americanbankingnews.comCongress Asset Management Co. Purchases 22,579 Shares of Vericel Co. (NASDAQ:VCEL)June 7 at 6:48 AM | marketbeat.comVericel Co. (NASDAQ:VCEL) Given Average Recommendation of "Buy" by AnalystsJune 7 at 3:31 AM | marketbeat.comPortside Wealth Group LLC Buys New Position in Vericel Co. (NASDAQ:VCEL)June 6, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 16,466 Shares of Vericel Co. (NASDAQ:VCEL)June 3, 2025 | marketbeat.comWellington Management Group LLP Buys 701,064 Shares of Vericel Co. (NASDAQ:VCEL)May 30, 2025 | marketbeat.comVoloridge Investment Management LLC Acquires Shares of 27,345 Vericel Co. (NASDAQ:VCEL)May 30, 2025 | marketbeat.comVericel's (VCEL) Overweight Rating Reiterated at StephensMay 24, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AGMay 24, 2025 | marketbeat.com5VCEL : What Analysts Are Saying About Vericel StockMay 23, 2025 | benzinga.comVericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial MarketsMay 23, 2025 | marketbeat.comRafferty Asset Management LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)May 22, 2025 | marketbeat.comLazard Asset Management LLC Purchases 5,923 Shares of Vericel Co. (NASDAQ:VCEL)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Purchases Shares of 80,696 Vericel Co. (NASDAQ:VCEL)May 21, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Holdings Raised by D. E. Shaw & Co. Inc.May 20, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 124,122 Shares of Vericel Co. (NASDAQ:VCEL)May 19, 2025 | marketbeat.comVericel at BofA Securities Conference: Growth and Innovation in HealthcareMay 17, 2025 | investing.comVericel Co. (NASDAQ:VCEL) Given Consensus Rating of "Buy" by BrokeragesMay 15, 2025 | marketbeat.comStockNews.com Downgrades Vericel (NASDAQ:VCEL) to SellMay 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVALN, VCEL, NAMS, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$29.90 +0.02 (+0.07%) As of 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.NewAmsterdam Pharma NASDAQ:NAMS$21.84 +1.68 (+8.33%) Closing price 04:00 PM EasternExtended Trading$22.22 +0.38 (+1.72%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Valneva NASDAQ:VALN$6.16 +0.09 (+1.40%) Closing price 03:59 PM EasternExtended Trading$6.11 -0.06 (-0.96%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.Vericel NASDAQ:VCEL$45.70 +1.88 (+4.29%) Closing price 04:00 PM EasternExtended Trading$45.70 +0.00 (+0.01%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
